Inspire Medical Systems, Inc. (INSP) Stock Price
INSPStock
$68.79−11.06%52W
Market Cap$1.99B
P/E13.68x
PEG Ratio—
Div yield—
Beta0.64
INSP Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)11.14%
Price vs S&P 500 (4W)-7.83%
VGM Score68.15
P/E Ratio (Annual)13.68x
INSP Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.25 | $0.14 | +157.10%(+$0.39) | |
| Q1 2026 | -$0.26 | $0.10 | +138.36%(+$0.36) | |
| Q4 2025 | $0.68 | $1.65 | +142.05%(+$0.97) | |
| Q3 2025 | -$0.17 | $0.38 | +323.63%(+$0.55) | |
| Q2 2025 | $0.20 | $0.45 | +120.34%(+$0.25) |
INSP Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
3.42
3.44
3.42
3.46
Industry Peers — Surgical & Medical Instruments(142)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
INSPInspire Medical Systems, Inc. | B | B | B | 2.2x | 51.2% | 86.1% | 6.0% | $68.79 |
| SYKStryker Corporation | C | B | C | 4.4x | 11.8% | 65.3% | 21.3% | $294.66 |
| MMM3M Company | C | D | B | 3.4x | -5.0% | 39.4% | 18.4% | $164.75 |
| BSXBoston Scientific Corp. | C | B | C | 3.1x | 15.2% | 69.5% | 19.8% | $44.39 |
| BDXBecton, Dickinson and Co. | B | D | A | 2.5x | 6.3% | 46.7% | 9.6% | $191.75 |
| MDLNMedline Inc. Class A common stock | C | D | C | 1.6x | — | 26.2% | 6.0% | $35.96 |
| RMDResMed Inc. | C | C | B | 5.9x | 12.1% | 61.1% | 33.4% | $238.97 |
| DXCMDexCom, Inc. | C | B | B | 6.5x | 19.3% | 64.3% | 22.9% | $86.04 |
| WSTWest Pharmaceutical Services, Inc. | D | C | A | 8.5x | 7.4% | 36.8% | 20.4% | $384.02 |
| SOLVSolventum Corporation | C | C | B | 1.8x | — | 54.8% | 23.9% | $85.81 |
| BAXBaxter International Inc. | B | D | B | 1.1x | -0.8% | 30.7% | -2.3% | $25.28 |
About Inspire Medical Systems, Inc.
Inspire Medical Systems develops and commercializes the Inspire system, a minimally invasive neurostimulation technology for treating moderate to severe obstructive sleep apnea. The company distributes its product through hospitals and ambulatory surgery centers, with the majority of revenue derived from the United States market and growing operations in Europe and the Asia Pacific region.